Results 1 to 10 of about 304,780 (265)
Polycythemia vera: historical oversights, diagnostic details, and therapeutic views [PDF]
Leukemia, 2021 Polycythemia vera (PV) is a relatively indolent myeloid neoplasm with median survival that exceeds 35 years in young patients, but its natural history might be interrupted by thrombotic, fibrotic, or leukemic events, with respective 20-year rates of 26%,
Ayalew Tefferi +2 more
openalex +2 more sources
Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b [PDF]
Leukemia, 2022 TO THE EDITOR: Interferon alfa not only restores normal blood cell counts in patients with polycythemia vera (PV) but can diminish the mutant JAK2 V617F allele burden [1 – 3].
Jean‐Jacques Kiladjian +28 more
openalex +2 more sources
Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia [PDF]
Revista Brasileira de Hematologia e Hemoterapia, 2011 BACKGROUND: The detection of molecular and cytogenetic alterations is important for the diagnosis, prognosis and classification of myeloproliferative neoplasms. OBJECTIVE: The aim of this study was to detect the following mutations: JAK2 V617F, JAK2 exon
Leonardo Caires dos Santos +5 more
doaj +4 more sources
Givinostat: an emerging treatment for polycythemia vera
Expert Opinion on Investigational Drugs, 2020 Introduction Polycythemia vera (PV), a Philadelphia chromosome-negative myeloproliferative neoplasm, is characterized by panmyelosis, pancytosis, and a JAK2 mutation.
Helen T. Chifotides +2 more
openalex +3 more sources
Impending anterior ischemic optic neuropathy with elements of retinal vein occlusion in a patient on interferon for polycythemia vera [PDF]
Clinical Ophthalmology, 2012 Kelly S Rue, Louis K Hirsch, Alfredo A SadunDepartment of Neuro-Ophthalmology, Doheny Eye Institute and Keck School of Medicine, University of Southern California, Los Angeles, CA, USAAbstract: We describe the course and likely pathophysiology of ...
Rue KS, Hirsch LK, Sadun AA
doaj +3 more sources
PLoS ONE, 2020 The myeloproliferative neoplasms, polycythemia vera, essential thrombocytosis and primary myelofibrosis are hematopoietic stem cell disorders and share driver mutations that either directly activate the thrombopoietin receptor, MPL, or activate it ...
Jerry L Spivak +8 more
doaj +2 more sources
Haematologica, 2019 Although it is well known that myeloproliferative neoplasms occur in younger patients, few large cohorts of such patients have been reported. Thus, our knowledge about circumstances of diagnosis, outcome and treatment is limited, especially for children ...
Jean-Christophe Ianotto +5 more
doaj +2 more sources
Haematologica, 2020 We report the final 2-year end-of-study results from the first clinical trial investigating combination treatment with ruxolitinib and low-dose pegylated interferon-α2 (PEG-IFNα2).
Anders Lindholm Sørensen +19 more
doaj +2 more sources
Introducing heat-not-burn tobacco improves hematocrit and cigarette smoking-related symptoms in patients with smokers' polycythemia and polycythemia vera. [PDF]
PLoS ONECigarette smoking induces relative and absolute erythrocytosis (smokers' polycythemia). In patients with smokers' polycythemia complicated by chronic obstructive pulmonary disease, the incidence and mortality rate of pulmonary embolism increase ...
Kazuhide Iizuka +17 more
doaj +2 more sources
Schizophrenia and Polycythemia Vera: A Case Report [PDF]
European PsychiatryIntroduction Schizophrenia is a severe mental disorder marked by abnormal interpretations of reality, often resulting in hallucinations, delusions, and disordered thinking that significantly impairs daily functioning and can be disabling.
N. El Moussaoui +4 more
doaj +2 more sources